SB-210313 analogs (SmithKline Beecham)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameSB-210313 analogs (SmithKline Beecham)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 α mitogen-activated protein kinase inhibitors
TargetsP38 α mitogen-activated protein kinase
Therapy Area/IndicationsInflammationInflammatory Bowel DiseasesArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSmithkline Beecham Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSmithkline Beecham Pharmaceuticals
Active IndicationsN/A
Inactive IndicationsInflammationInflammatory Bowel DiseasesArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A